Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.50 |
| ▸ | CES1 | P23141 | 2/20 | 0.50 |
| ▸ | KIF11 | P52732 | 3/20 | 0.44 |
| ▸ | GSK3B | P49841 | 2/20 | 0.44 |
| ▸ | ACP3 | P15309 | 1/20 | 0.43 |
| ▸ | GRM8 | O00222 | 1/20 | 0.43 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.42 |
| ▸ | HTR3B | O95264 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.42 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23182220 | 0.84 | CES2 (0.50) | CES2CES1GSK3BACP3GRM8 | |
| SCHEMBL11902072 | 0.84 | GRM8 (0.50) | CES2CES1KIF11ACP3GRM8 | |
| SCHEMBL18125936 | 0.84 | GRM8 (0.50) | CES2CES1KIF11ACP3GRM8 | |
| SCHEMBL5225725 | 0.84 | GRM8 (0.50) | CES2CES1KIF11ACP3GRM8 | |
| SCHEMBL6214993 | 0.83 | RORC (0.50) | — | |
| SCHEMBL1061611 | 0.82 | CES2 (0.52) | CES2CES1KIF11GSK3BACP3 | |
| SCHEMBL7470401 | 0.80 | CES2 (0.65) | CES2CES1KIF11GSK3BACP3 | |
| SCHEMBL28200284 | 0.80 | CES2 (0.50) | CES2CES1KIF11GSK3BACP3 | |
| SCHEMBL7289441 | 0.78 | CES2 (0.49) | CES2CES1KIF11GSK3BACP3 | |
| SCHEMBL2055563 | 0.78 | EPHX1 (0.53) | CES2CES1KIF11GSK3BACP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999731-B2 | EGFR dimer disruptors and use of the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-06-04 | — | — | US | disclosed |
| US-20220340572-A1 | EGFR DIMER DISRUPTORS AND USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2022-10-27 | — | — | US | disclosed |
| US-11358965-B2 | EGFR dimer disruptors and use of the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-06-14 | — | — | US | disclosed |
| EP-3755323-A1 | EGFR DIMER DISRUPTORS AND USE OF THE SAME | The Regents Of The University Of Michigan (US) | 2020-12-30 | — | — | EP | disclosed |
| US-20200377503-A1 | EGFR DIMER DISRUPTORS AND USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2020-12-03 | — | — | US | disclosed |
| CN-111886009-A | EGFR dimer disruptors and uses thereof | 密歇根大学董事会 | 2020-11-03 | — | — | CN | disclosed |
| WO-2019165358-A1 | EGFR DIMER DISRUPTORS AND USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-08-29 | — | — | WO | disclosed |
| US-20110059940-A1 | 2-Aryl Glycinamide Derivatives | BRISTOL- MYERS SQUIBB COMPANY | 2011-03-10 | — | — | US | disclosed |
| EP-2278878-A1 | 2-ARYL GLYCINAMIDE DERIVATIVES | Bristol-Myers Squibb Company (US) | 2011-02-02 | — | — | EP | disclosed |
| US-20110009440-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | MARSHALL HOWARD ROBERT | 2011-01-13 | — | — | US | disclosed |
| US-7592488-B2 | Method for preparing optically active amines | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2009-09-22 | — | — | US | disclosed |
| US-20090062360-A1 | Compounds Which Inhibit the Glycine Transporter and Uses Thereof | GLAXO GROUP LIMITED (GB) | 2009-03-05 | — | — | US | disclosed |
| US-20090062360-A1 | Compounds Which Inhibit the Glycine Transporter and Uses Thereof | GLAXO GROUP LIMITED (GB) | 2009-03-05 | — | — | US | disclosed |
| US-20090035830-A1 | Method for Preparing Optically Active Amines | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2009-02-05 | — | — | US | disclosed |
| US-20090035830-A1 | Method for Preparing Optically Active Amines | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2009-02-05 | — | — | US | disclosed |
| EP-1994010-A1 | COMPOUNDS WHICH INHIBIT THE GLYCINE TRANSPORTER AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2008-11-26 | — | — | EP | disclosed |
| WO-2008092879-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-08-07 | — | — | WO | disclosed |
| WO-2007116061-A1 | 1-(2-ARYL-2-OXOETHYL)-3-PHENYL-1, 4-DIAZASPIRO [4.5]DEC-3-EN-2-ONE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007104775-A1 | COMPOUNDS WHICH INHIBIT THE GLYCINE TRANSPORTER AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007104775-A1 | COMPOUNDS WHICH INHIBIT THE GLYCINE TRANSPORTER AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11358965-B2 | EGFR dimer disruptors and use of the same | EGFR, ERBB2, ERBB4 | CES2 4007/4885CES1 3981/4885KIF11 2884/4885 |
| US-20090062360-A1 | Compounds Which Inhibit the Glycine Transporter and Uses Thereof | SLC18A2, SLC1A2, SLC1A1 | CES2 1379/4885CES1 1192/4885KIF11 3266/4885 |
| US-20220340572-A1 | EGFR DIMER DISRUPTORS AND USE OF THE SAME | EGFR, ERBB2, ERBB4 | CES2 4007/4885CES1 3981/4885KIF11 2884/4885 |
| US-20110059940-A1 | 2-Aryl Glycinamide Derivatives | IAPP, APP, BACE1 | CES2 2407/4885CES1 1809/4885KIF11 4485/4885 |
| US-20110009440-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | SLC18A2, SLC1A2, SLC1A1 | CES2 443/4885CES1 392/4885KIF11 2136/4885 |
| US-20090035830-A1 | Method for Preparing Optically Active Amines | CEL, NAAA, LIPA | CES2 17/4885CES1 28/4885KIF11 2325/4885 |
| US-11999731-B2 | EGFR dimer disruptors and use of the same | EGFR, ERBB2, ERBB4 | CES2 4007/4885CES1 3981/4885KIF11 2884/4885 |
| US-20200377503-A1 | EGFR DIMER DISRUPTORS AND USE OF THE SAME | EGFR, ERBB2, ERBB4 | CES2 4007/4885CES1 3981/4885KIF11 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.